466 related articles for article (PubMed ID: 37238714)
1. Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease.
Ito G; Utsunomiya-Tate N
Biomolecules; 2023 May; 13(5):. PubMed ID: 37238714
[TBL] [Abstract][Full Text] [Related]
2. Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology.
Mamais A; Manzoni C; Nazish I; Arber C; Sonustun B; Wray S; Warner TT; Cookson MR; Lewis PA; Bandopadhyay R
Brain Res; 2018 Dec; 1701():75-84. PubMed ID: 30055128
[TBL] [Abstract][Full Text] [Related]
3. The Cell Biology of LRRK2 in Parkinson's Disease.
Usmani A; Shavarebi F; Hiniker A
Mol Cell Biol; 2021 Apr; 41(5):. PubMed ID: 33526455
[TBL] [Abstract][Full Text] [Related]
4. GTP-binding inhibitors increase LRRK2-linked ubiquitination and Lewy body-like inclusions.
Thomas JM; Wang X; Guo G; Li T; Dai B; Nucifora LG; Nucifora FC; Liu Z; Xue F; Liu C; Ross CA; Smith WW
J Cell Physiol; 2020 Oct; 235(10):7309-7320. PubMed ID: 32180220
[TBL] [Abstract][Full Text] [Related]
5. LRRK2 Structure-Based Activation Mechanism and Pathogenesis.
Zhang X; Kortholt A
Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189360
[TBL] [Abstract][Full Text] [Related]
6. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
[TBL] [Abstract][Full Text] [Related]
7. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors.
Pajarillo E; Rizor A; Lee J; Aschner M; Lee E
Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588
[TBL] [Abstract][Full Text] [Related]
8. Pathological Functions of LRRK2 in Parkinson's Disease.
Jeong GR; Lee BD
Cells; 2020 Nov; 9(12):. PubMed ID: 33266247
[TBL] [Abstract][Full Text] [Related]
9. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.
Giordana MT; D'Agostino C; Albani G; Mauro A; Di Fonzo A; Antonini A; Bonifati V
Mov Disord; 2007 Jan; 22(2):275-8. PubMed ID: 17149743
[TBL] [Abstract][Full Text] [Related]
10. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.
Gaig C; Martí MJ; Ezquerra M; Rey MJ; Cardozo A; Tolosa E
J Neurol Neurosurg Psychiatry; 2007 Jun; 78(6):626-8. PubMed ID: 17210620
[TBL] [Abstract][Full Text] [Related]
11. LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.
Dzamko N; Gysbers AM; Bandopadhyay R; Bolliger MF; Uchino A; Zhao Y; Takao M; Wauters S; van de Berg WD; Takahashi-Fujigasaki J; Nichols RJ; Holton JL; Murayama S; Halliday GM
Mov Disord; 2017 Mar; 32(3):423-432. PubMed ID: 27911006
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.
Cao R; Chen C; Wen J; Zhao W; Zhang C; Sun L; Yuan L; Wu C; Shan L; Xi M; Sun H
Bioorg Chem; 2023 Dec; 141():106906. PubMed ID: 37837728
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants.
Verma M; Callio J; Otero PA; Sekler I; Wills ZP; Chu CT
J Neurosci; 2017 Nov; 37(46):11151-11165. PubMed ID: 29038245
[TBL] [Abstract][Full Text] [Related]
14. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.
Seol W
BMB Rep; 2010 Apr; 43(4):233-44. PubMed ID: 20423607
[TBL] [Abstract][Full Text] [Related]
16. [Clinical molecular genetics for PARK8 (LRRK2)].
Tomiyama H; Hatano T; Hattori N
Brain Nerve; 2007 Aug; 59(8):839-50. PubMed ID: 17713120
[TBL] [Abstract][Full Text] [Related]
17. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
Monfrini E; Di Fonzo A
Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
[TBL] [Abstract][Full Text] [Related]
18. LRRK2 and mitochondria: Recent advances and current views.
Singh A; Zhi L; Zhang H
Brain Res; 2019 Jan; 1702():96-104. PubMed ID: 29894679
[TBL] [Abstract][Full Text] [Related]
19. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.
Gandhi PN; Chen SG; Wilson-Delfosse AL
J Neurosci Res; 2009 May; 87(6):1283-95. PubMed ID: 19025767
[TBL] [Abstract][Full Text] [Related]
20. LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons.
Henderson MX; Changolkar L; Trojanowski JQ; Lee VMY
J Parkinsons Dis; 2021; 11(3):1187-1196. PubMed ID: 33720852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
